Search Result

Isoforms Recommended:	AMPA Receptor

Results for "

AMPA+receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) Akt (7) AMPK (2) Apoptosis (5) Autophagy (2) c-Met/HGFR (3) Calcium Channel (8) CaMK (2) Carbonic Anhydrase (7) Caspase (2) Cytochrome P450 (2) Dopamine Transporter (1) Drug Derivative (2) Endogenous Metabolite (2) Environmental Pollutants (1) ERK (2) Ferroptosis (2) GABA Receptor (9) Glutaminase (3) iGluR (129) Isotope-Labeled Compounds (8) Keap1-Nrf2 (2) Lipoxygenase (1) MMP (5) mTOR (2) NF-κB (5) Opioid Receptor (5) p38 MAPK (2) PARP (2) Phosphatase (2) Phosphodiesterase (PDE) (1) PI3K (7) PKC (3) Potassium Channel (7) Reactive Oxygen Species (ROS) (1) Reference Standards (15) Sodium Channel (9) STING (2) Tyrosinase (3) VEGFR (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (4) Inflammation/Immunology (9) Metabolic Disease (7) Neurological Disease (131)

By Targets:

11β-HSD (2)

Akt (7)

AMPK (2)

Apoptosis (5)

Autophagy (2)

c-Met/HGFR (3)

Calcium Channel (8)

CaMK (2)

Carbonic Anhydrase (7)

Caspase (2)

Cytochrome P450 (2)

Dopamine Transporter (1)

Drug Derivative (2)

Endogenous Metabolite (2)

Environmental Pollutants (1)

ERK (2)

Ferroptosis (2)

GABA Receptor (9)

Glutaminase (3)

iGluR (129)

Isotope-Labeled Compounds (8)

Keap1-Nrf2 (2)

Lipoxygenase (1)

MMP (5)

mTOR (2)

NF-κB (5)

Opioid Receptor (5)

p38 MAPK (2)

PARP (2)

Phosphatase (2)

Phosphodiesterase (PDE) (1)

PI3K (7)

PKC (3)

Potassium Channel (7)

Reactive Oxygen Species (ROS) (1)

Reference Standards (15)

Sodium Channel (9)

STING (2)

Tyrosinase (3)

VEGFR (2)

By Research Areas:

Cancer (7)

Cardiovascular Disease (4)

Inflammation/Immunology (9)

Metabolic Disease (7)

Neurological Disease (131)

136

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15068

NBQX Maximum Cited Publications 20 Publications Verification FG9202	iGluR	Neurological Disease
NBQX (FG9202) is a highly selective and competitive *AMPA receptor* antagonist. NBQX has neuroprotective and anticonvulsant activity .

HY-B0122

Topiramate 5+ Cited Publications McN 4853; RWJ 17021	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of *kainate/AMPA* receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-100815A

(S)-AMPA L-AMPA	iGluR	Neurological Disease
(S)-AMPA (L-AMPA), an active S-enantiomer of AMPA, is a potent and selective *AMPA receptor* agonist .

HY-115864

Osavampator TAK-653; NBI-1065845	iGluR Lipoxygenase	Neurological Disease
Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC₅₀ = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders .

HY-15068A

NBQX disodium Maximum Cited Publications 20 Publications Verification FG9202 disodium	iGluR	Neurological Disease
NBQX disodium (FG9202 disodium) is a highly selective and competitive *AMPA receptor* antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .

HY-10933

CX516 2 Publications Verification BDP 12	iGluR	Neurological Disease
CX516 (BDP 12) is an ampakine and acts as an *AMPA* receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .

HY-101528

IDRA 21	iGluR	Neurological Disease
IDRA 21 is a positive and orally active modulator of the *AMPA* receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging .

HY-110175

CX614 1 Publications Verification	iGluR	Neurological Disease
CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .

HY-10934

Mibampator LY451395	iGluR	Neurological Disease
Mibampator (LY451395) is a potent and highly selective potentiator of the AMPA receptors.

HY-175443

AMPA-IN-3	iGluR	Neurological Disease
AMPA-IN-3 is an *AMPA* receptor inhibitor. AMPA-IN-3 inhibits TARP J2-dependent AMPA receptor activity with a pIC₅₀ value of 10.7. A AMPA-IN-3 can be used for the research of neurological disease .

HY-12509

PEPA	iGluR	Neurological Disease
PEPA is an *AMPA receptor* allosteric potentiator. PEPA shows preferential action of PEPA on the flop form of AMPA receptors. PEPA is a more potent suppressor of desensitization of receptors containing GluR3 and GluR4 as opposed to those containing GluR1. PEPA has antianxiety effects .

HY-12506A

Naspm trihydrochloride 5+ Cited Publications 1-Naphthylacetyl spermine trihydrochloride	iGluR	Neurological Disease
Naspm trihydrochloride (1-Naphthylacetyl spermine trihydrochloride), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-12506

Naspm 5+ Cited Publications 1-Naphthylacetyl spermine	iGluR	Neurological Disease
Naspm (1-Naphthyl acetyl spermine), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-15079

Talampanel 1 Publications Verification GYKI-53773; LY-300164	iGluR Apoptosis	Neurological Disease Cancer
Talampanel (LY300164) is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor antagonis with anti-seizure activity . Talampanel (IVAX) has neuroprotective effects in rodent stroke models . Talampanel attenuates caspase-3 dependent apoptosis in mouse brain .

HY-100785

gamma-DGG γDGG; γ-D-Glutamylglycine	iGluR	Neurological Disease
gamma-DGG is a competitive *AMPA receptor* blocker.

HY-139897

CX 717	iGluR	Neurological Disease
CX 717 is a positive allosteric modulator of *AMPA receptor*. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD) .

HY-W015309S1

Decanoic acid-d19	Isotope-Labeled Compounds iGluR	Neurological Disease
Decanoic acid-d₁₉9 is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-177873

AMPA receptor modulator-10	iGluR	Neurological Disease
AMPA receptor modulator-10 (Compound 9a) is an orally active *AMPA receptor* (AMPAR) positive allosteric modulator. AMPA receptor modulator-10 exhibits potent activity (pEC₅₀ = 5.0) on the GluA2 subtype of AMPAR, significantly enhancing glutamate-induced calcium influx and current responses. AMPA receptor modulator-10 can reverse the memory impairment induced by Scopolamine (HY-N0296) and enhance cognitive function. AMPA receptor modulator-10 can be used for the research of neurological disease, such as schizophrenia .

HY-109046

Tulrampator 2 Publications Verification CX-1632; S-47445	iGluR mTOR	Neurological Disease
Tulrampator (S-47445) is an orally active selective *AMPA receptor* modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder .

HY-18663

CP-465022 1 Publications Verification	iGluR	Neurological Disease
CP-465022 is a potent, and selective noncompetitive *AMPA receptor* antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀ of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-112781

Pesampator PF-04958242	iGluR	Neurological Disease
Pesampator (PF-04958242) is a potent and highly selective positive allosteric modulator of *AMPA receptor* (an AMPA potentiator) with an EC₅₀ of 310 nM and a K_i of 170 nM .

HY-107520

MNI-caged-L-glutamate	Drug Derivative	Neurological Disease
MNI-caged-L-glutamate is an inert photolabile glutamate precursor. MNI-caged-L-glutamate does not modulate NMDA and *AMPA* receptor function in cultured neurones. MNI-caged-L-glutamate can be used for research on neurotransmitters .

HY-108707

LY3130481 1 Publications Verification	iGluR	Neurological Disease
LY3130481 is an orally available *AMPA* receptor antagonist, selectively inhibiting the IC₅₀ value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .

HY-10937

Farampator CX-691; Org24448	iGluR	Neurological Disease
Farampator (CX-691;Org24448) is an *AMPA* receptor positive modulator.

HY-10935

LY450108 1 Publications Verification	iGluR	Neurological Disease
LY450108 is a potent *AMPA* receptor potentiator. LY450108 has the potential for depression and Parkinson's disease research .

HY-136275

AMPA receptor modulator-2	iGluR	Others
AMPA receptor modulator-2 (Example 134) is a *AMPA receptor* modulator, with a pIC₅₀ of 10.1 for TARPγ8 dependent AMPA receptor . pIC₅₀ = -lgIC₅₀.

HY-15072

Zonampanel YM 872	iGluR	Metabolic Disease
Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor.

HY-18689

SYM2206	iGluR	Neurological Disease
SYM2206 is a potent and non-competitive *AMPA receptor* antagonist, with an IC₅₀ of 1.6 μM. SYM2206 blocks Na_v1.6-mediated persistent currents .

HY-12508

CMPDA	iGluR	Neurological Disease
CMPDA is a positive allosteric modulator of AMPA receptors with EC50s of 45.4 ± 4.2 nM/63.4 ± 5.6 nM for GluA2i/GluA2o receptor.

HY-15071

YM90K	iGluR	Neurological Disease
YM90K is a potent and selective *AMPA receptor* antagonist with a K_i of 84 nM. YM90K is less potent in inhibiting kainate (K_i of 2.2 μM) and NMDA (K_i of 37 μM) receptors. YM90K has neuroprotective actions .

HY-101216

Org-26576	iGluR	Neurological Disease
Org-26576 is a *AMPA* receptor positive allosteric modulator.

HY-W015309S3

Decanoic acid-d5	iGluR	Neurological Disease
Decanoic acid-d₅ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-107606A

UBP301 hydrochloride	iGluR	Neurological Disease
UBP301 hydrochloride is a potent and selective antagonist of kainate receptor with IC₅₀ and K_D of 164 μM and 5.94 μM, respectively. UBP301 hydrochloride has ～30-fold selectivity of kainate receptor over AMPA receptor. UBP301 hydrochloride is the derivative of willardiine .

HY-B0122R

Topiramate (Standard) McN 4853 (Standard); RWJ 17021 (Standard)	Reference Standards iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-155628

AMPA receptor modulator-6	iGluR	Others
AMPA receptor modulator-6 is an *AMPA* receptor positive allosteric modulator (PAM). AMPA receptor modulator-6 can be used in the study of neurological diseases .

HY-101363

1-BCP Piperonylic acid piperidide	iGluR	Neurological Disease
1-BCP (Piperonylic acid piperidide) is a centrally active agent that modulates *AMPA receptor* gated currents. 1-BCP is a memory-enhancing agent .

HY-105860

Selurampanel BGG 492	iGluR	Neurological Disease
Selurampanel (BGG 492) is an orally active and competitive *AMPA receptor* antagonist with an IC₅₀ of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research .

HY-W015309S

Decanoic acid-d3	iGluR	Neurological Disease
Decanoic acid-d₃ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-103229

Cl-HIBO	iGluR	Neurological Disease
Cl-HIBO is a highly subtype-selective GluR1/2 agonist (EC₅₀=4.7 and 1.7 μM, respectively). Cl-HIBO is a potent *AMPA receptor* agonist (IC₅₀=0.22 μM). Cl-HIBO has desensitizing properties .

HY-14451

PF-4778574	iGluR	Neurological Disease
PF-4778574 is a positive allosteric modulation of *AMPA* receptor with EC₅₀ of 45 to 919 nM in differenct cells.

HY-145761

AMPA-IN-1	iGluR	Neurological Disease
AMPA-IN-1 is a potent inhibitor of *AMPA* receptor. AMPA receptors are receptors that are widely expressed in the brain, and play a central role in the regulation of fast excitatory synaptic transmission and synaptic plasticity. AMPA-IN-1 has the potential for the research of various central diseases including epilepsy (extracted from patent WO2017082288A1, compound 14) .

HY-154798

AMPA receptor modulator-5	iGluR	Neurological Disease
AMPA receptor modulator-5 (Example 217) is an *AMPA receptor* modulator. AMPA receptor modulator-5 can be used for research of neurological disease .

HY-136905

AMPA receptor antagonist-2	iGluR	Others
AMPA receptor antagonist-2 (example 23) is an *AMPA receptor* antagonist .

HY-161090

AMPA receptor modulator-7	iGluR	Neurological Disease
AMPA receptor modulator-7 (compound 36) is a modulator of *AMPA receptor. AMPA receptor* modulator-7 has oral activity and can penetrate the blood-brain barrier .

HY-145959

AMPA receptor antagonist-3	iGluR	Neurological Disease
AMPA receptor antagonist-3 is an *AMPA receptor* antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders .

HY-122150

AMPA receptor modulator-3	iGluR	Neurological Disease
AMPA receptor modulator-3 is an allosteric *AMPA* receptor modulator (EC₅₀: 4.4 μM). AMPA receptor modulator-3 can be used in the research of mammalian nervous system, such as learning and memory .

HY-136844

LY-300168 GYKI 53655	iGluR	Neurological Disease
LY 300168 (GYKI 53655) is a non-competitive, blood-brain-barrier permeable *AMPA receptor* antagonist. LY 300168 attenuates hippocampal injury. LY 300168 blocks the sound-induced clonic and tonic convulsions .

HY-15068AR

NBQX disodium (Standard) FG9202 disodium (Standard)	iGluR Reference Standards	Neurological Disease
NBQX (disodium) (Standard) is the analytical standard of NBQX (disodium). This product is intended for research and analytical applications. NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .

HY-149975

AMPA receptor modulator-4	iGluR	Neurological Disease
AMPA receptor modulator-4, a 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BTD), is an orally active positive allosteric modulator of the AMPA receptors (AMPAR PAMs). AMPA receptor modulator-4 can cross the blood-brain barrier. AMPA receptor modulator-4 increases the cognition performance and improves working memory performance in mice .

HY-103235

NPEC-caged-(S)-AMPA	iGluR	Neurological Disease
NPEC- caged-(S)-AMPA, a caged neurotransmitter analog, is a NPEC photoprotecting group caged the (S)-AMPA (HY-100815A) to make caged ligands specific for glutamate receptor sub-types. NPEC- caged-(S)-AMPA selectively activates *AMPA receptor* .

Cat. No.	Product Name	Target	Research Area

HY-P1367

Pep1-TGL	Peptides	Neurological Disease
Pep1-TGL is a synthetic peptide containing the TGL motif from the C-terminus of the AMPA receptor GluA1 subunit .

HY-P1057

Pep4c	iGluR	Neurological Disease
Pep4c is an inactive control peptide for Pep2m (HY-P1058). Pep4c lacks functional activity to disrupt Protein Interacting with C Kinase 1 (PICK1)-AMPA* receptor* (GluA2) or N-ethylmaleimide-sensitive factor (NSF)-GluA2 interactions. Pep4c is used as a negative control in experiments to validate the specificity of Pep2m's effects on *AMPA* receptor trafficking and synaptic plasticity ^{[1] [2] [3] [4] [5] [6]}.

HY-P3340

Leptin (116-130)	iGluR	Neurological Disease
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .

HY-P3355

p-fin4	iGluR	Neurological Disease
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P5487

GluR23Y	iGluR	Others
GluR23Y is a biological active peptide. (This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.)

HY-P3354

p3Ysh-3	iGluR	Neurological Disease
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P1055

Pep2-SVKE	iGluR	Neurological Disease
Pep2-SVKE is an inactive control peptide for pep2-SVKI (HY-P1056). Pep2-SVKE is an inhibitory peptide corresponding to the last 10 amino acids of the C-terminus of the GluR2 *AMPA* receptor subunit. Pep2-SVKE does not block *AMPA*-mediated [ ³H]DA exocytosis. Pep2-SVKE does not bind to GRIP or PICK43 and does not block retention of PICK1 by GST-GluR2 and LTD ^{[1] [2] [3] [4] [5]}.

HY-P1056

pep2-SVKI	iGluR	Neurological Disease
pep2-SVKI is a selective peptide inhibitor. pep2-SVKI inhibits the binding of AMPA-type glutamate receptor (GluA2) (C-terminal PDZ site) to glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP), and C-kinase interacting protein (PICK1). pep2-SVKI increases the amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD). pep2-SVKI can be used to study neurological diseases .

HY-P1058

Pep2m	iGluR	Neurological Disease
Pep2m is a peptide receptor inhibitor. Pep2m inhibits the interaction between the C-terminus of the AMPA-type glutamate receptor (GluA2) subunit and N-ethylmaleimide-sensitive fusion protein (NSF). Pep2m prevents synaptic long-term depression (LTD). Pep2m can reduce postsynaptic currents in neurons, AMPA-mediated currents in cultured hippocampal neurons, and AMPA receptor surface expression ^{[1] [2] [3] [4] [5]}.

HY-P1059

Pep2-AVKI	iGluR	Neurological Disease
Pep2-AVKI is a selective peptide inhibitor of the binding of the AMPA receptor subunit (GluR2) at the C-terminal PDZ site to C-kinase (PICK1). Pep2-AVKI does not affect the binding of (AMPA-type glutamate receptor) GluA2 to GRIP or ABP. Pep2-AVKI does not increase the amplitude of AMPA currents. pep2-AVKI can be used to study neurological diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W015309

Decanoic acid 4 Publications Verification	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Biological Pesticide Research Source Classification Agricultural Research	Environmental Pollutants Endogenous Metabolite iGluR Glutaminase c-Met/HGFR Tyrosinase
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of *AMPA* receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of *AMPA* receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-W015309R

Decanoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards iGluR Tyrosinase c-Met/HGFR Glutaminase
Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-N0660R

Jujuboside B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of *AMPA* receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.

Cat. No.	Product Name	Chemical Structure

HY-W015309S1

Decanoic acid-d19
Decanoic acid-d₁₉9 is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-W266188

Decanoic acid-13C

Decanoic acid- ¹³C is the ¹³C-labeled Decanoic acid (HY-W015309). Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-W015309S3

Decanoic acid-d5
Decanoic acid-d₅ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-W015309S

Decanoic acid-d3
Decanoic acid-d₃ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-B0122S

Topiramate-13C6

Topiramate-13C6 (McN 4853-13C6) is the ¹³C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-90003S

Tianeptine-d12

Tianeptine-d₁₂ is a deuterated analog of Tianeptine (HY-90003).Tianeptine is an atypical antidepressant. Tianeptine is a moderate-intensity agonist of the μ-opioid receptor (MOR), and to a lesser extent, is an agonist of the δ-opioid receptor (DOR). Tianeptine is a glutamate modulator that can enhance AMPA receptor and antagonize NMDA receptor. Tianeptine increases sensitivity of the α1 adrenergic receptor, which only manifests in chronic treatment. Tianeptine exerts neuroprotective effects under stress/inflammation-induced conditions, exhibiting anti-inflammatory and antioxidant properties. Tianeptine inhibits MMP-9 by suppressing the PI3K/Akt-mediated NF-κB pathway. Tianeptine can be used to alleviate symptoms of depression and anxiety, but does not cause sedative effects.

HY-W015309S2

Decanoic acid-d2
Decanoic acid-d₂ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-10933S

CX516-d10
CX516-d₁₀ is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .

HY-B0122S1

Topiramate-13C

Topiramate- ¹³C (McN 4853- ¹³C) is ¹³C labeled Topiramate. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-144224S

Tianeptine-d6 hydrochloride

Tianeptine-d₆ hydrochloride is the deuterium labeled Tianeptine hydrochloride. Tianeptine hydrochloride is an atypical antidepressant. Tianeptine hydrochloride is a moderate-intensity agonist of the μ-opioid receptor (MOR), and to a lesser extent, is an agonist of the δ-opioid receptor (DOR). Tianeptine hydrochloride is a glutamate modulator that can enhance AMPA receptor and antagonize NMDA receptor. Tianeptine hydrochloride increases sensitivity of the α1 adrenergic receptor, which only manifests in chronic treatment. Tianeptine hydrochloride exerts neuroprotective effects under stress/inflammation-induced conditions, exhibiting anti-inflammatory and antioxidant properties. Tianeptine hydrochloride inhibits MMP-9 by suppressing the PI3K/Akt-mediated NF-κB pathway. Tianeptine hydrochloride can be used to alleviate symptoms of depression and anxiety, but does not cause sedative effects.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks